BiotechTube
VistaPharm

VistaPharm

Miami, United States· Est.
vistapharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

VistaPharm is a long-standing, private commercial-stage company in the generic pharmaceuticals sector, with a focused mission on addiction treatment. Acquired by PAI Pharma, it leverages an expanded portfolio to serve a critical and growing market need. Its business model centers on manufacturing and distributing approved generic medications, emphasizing supply reliability, regulatory compliance, and customer support. The company operates without a proprietary technology platform, competing on quality, service, and portfolio breadth within a competitive generic drug landscape.

Substance Use DisorderAddiction Medicine

Technology Platform

Traditional generic pharmaceutical formulation, manufacturing, and ANDA regulatory strategy; no proprietary discovery platform.

Funding History

2
Total raised:$105M
Series B$75M
Series A$30M

Opportunities

The ongoing opioid epidemic and increased focus on treating substance use disorder create a large and sustained demand for generic medication-assisted treatment (MAT).
Policy trends favoring expanded access to care and cost containment in healthcare strongly incentivize the use of generic drugs.
The merger with PAI Pharma provides scale, a broader portfolio, and resources to pursue new ANDA filings and potentially expand into adjacent therapeutic areas.

Risk Factors

Intense competition in the generic drug industry leads to severe price erosion and margin pressure.
Significant regulatory risk from the FDA and DEA regarding manufacturing compliance and controlled substance handling; any violation could halt production.
Vulnerability to supply chain disruptions for APIs and dependence on continued favorable reimbursement policies for SUD treatments.

Competitive Landscape

VistaPharm competes in the crowded generic pharmaceuticals market, facing competition from large multinational generics manufacturers (e.g., Teva, Mylan) and other focused generic companies. Within the SUD niche, it competes on product portfolio breadth, reliability of supply, customer service, and cost. Its key differentiator is its dedicated mission and expertise in the SUD space, building loyalty with treatment centers.

More companies in Small Molecule Drugs →More companies in United States →